Ipsen Biopharmaceuticals, Inc. Announces FDA Approval of Dysport(R) (Abobotulinumtoxin A) for the Treatment of Lower Limb Spasticity in Pediatric Patients Aged Two and Older

BASKING RIDGE, N.J., Aug. 1, 2016 -- (Healthcare Sales & Marketing Network) -- Ipsen Biopharmaceuticals, Inc., a subsidiary of Ipsen SA (Euronext: IPN; ADR: IPSEY) (Ipsen), today announced that the U.S. Food and Drug Administration (FDA) has approved its ... Biopharmaceuticals, FDA Ipsen Biopharmaceuticals, Dysport, abobotulinumtoxin A, botulinum toxin

http://salesandmarketingnetwork.com/news_release_bs.html?ID=2041451

Source: HSMN NewsFeed - August 1, 2016 Category: Pharmaceuticals Source Type: news

More News: Abobotulinumtoxin A | Food and Drug Administration (FDA) | Marketing | Pediatrics | Pharmaceuticals